AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCY

我们研究的目标是提高无病存活率和总体 恶性血液病患者应用高分子肝素治疗的生存率 剂量治疗和自体干细胞移植。它的意图是 引入旨在提高效率和潜力的新方法 大剂量化疗或放化疗和干细胞支持的安全性 对于正在接受屈光性B细胞淋巴瘤治疗的患者， 霍奇金氏病和白血病。 这些创新包括使用高剂量序贯化疗治疗 复发性何杰金氏病的治疗及~(60)Y的应用 抗CD20抗原的单抗作为准备工作的一部分 自体骨髓移植患者的治疗方案 (BMT)用于B细胞淋巴瘤。我们也会研究可行性， 添加钇标记的单抗的有效性和毒性 自体骨髓移植患者的CD33或CD45抗原 急性髓系白血病和Ph染色体的治疗 Ph+阳性的急性淋巴细胞白血病(ALL)。此外，在这方面 我们将研究NW载体的使用，一种腺相关的 用于高效转导造血干细胞的病毒。这 方法旨在阐明造血的模式和程度 和免疫重建，以及复发的潜在原因 对接受低级别治疗的患者进行自体骨髓移植后发生 接受放射治疗和非放射治疗后的淋巴瘤。我们 还将研究使用核酶来切割杂交RNA 这是由于Ph+ALL的t(9；22)染色体易位所致 净化白血病患者外周血干细胞的目标 接受自体骨髓移植治疗这种疾病。 这些研究将测试新的方法，旨在减少主要 复发问题，这是成功使用的最大障碍 自体干细胞移植治疗恶性淋巴瘤 霍奇金氏病和急性白血病。该项目的重点是修改 治疗恶性肿瘤残存身体负担的准备方案 以及开发旨在净化干细胞的分子方法 污染白血病细胞的产物。最后，项目2将作为 实验项目的临床资源。

The goal of our study is to improve disease-free survival and overall survival in patients with hematologic malignancies through the use of high dose therapy and autologous stem cell grafting. It is the intent to introduce novel approaches designed to increase the efficacy and potential safety of high dose chemotherapy or chemoradiotherapy and stem cell support for patients who are undergoing treatment for refractors B cell lymphoma, Hodgkin's disease and leukemia. These innovations include using high dose sequential chemotherapy for the treatment of relapsed Hodgkin's disease and the use of yttrium labeled monoclonal antibodies to the CD20 antigen as part of the preparatory regimen for patients undergoing autologous bone marrow transplantation (BMT) for B cell lymphoma. We will also study the feasibility, effectiveness and toxicity of adding yttrium labeled monoclonal antibodies to either the CD33 or CD45 antigen in patients undergoing autologous BMT as treatment for acute myelogenous leukemia and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). In addition, in this project we will investigate the use of a nw vector, an adeno-associated virus for efficient transduction of hematopoietic stem cells. This approach is designed to elucidate the pattern and degree of hematopoietic and immune reconstitution, as well as the potential cause of relapse that occurs after autologous BMT for patients undergoing treatment for low grade lymphoma following radiation and non-radiation containing regimens. We will also study the use of a ribozyme designed to cleave the hybrid RNA that results from the t (9;22) chromosome translocation of Ph+ ALL with the goal to purge peripheral blood stem cells of leukemia in patients undergoing autologous BMT for this disorder. These studies will test novel methods designed to decrease the major problem of relapse, which is the greatest obstacle to successful use of autologous stem cell transplant for treatment of malignant lymphomas, Hodgkin's disease, and acute leukemia. The project focuses on modifying the preparatory regimen to treat the residual body burden of malignancy, a well as developing molecular methods designed to purge the stem cell product of contaminating leukemia cells. Finally, Project 2 will serve as a clinical resource for experimental Projects.